- Q1 2024 Tarsus Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2024$37.35 (-1.79%)Earnings
- Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2024$39.22 (+18.28%)Earnings
- Q3 2023 Tarsus Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023$15.57 (-5.86%)Earnings
- Tarsus Pharmaceuticals Inc To Discuss XDEMVY Approved For The Treatment Of Demodex Blepharitis Call TranscriptJul 25, 2023
- Tarsus Pharmaceuticals Inc To Discuss Creating the Next Blockbuster Category in Eye Care Call TranscriptJun 15, 2023
- Tarsus Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Tarsus Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Tarsus Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Tarsus Pharmaceuticals Inc To Discuss Revolutionizing Treatment For Demodex Blepharitis Patients Call TranscriptFeb 08, 2022
- Tarsus Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 08, 2021
- Tarsus Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Tarsus Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 22, 2021
- Tarsus Pharmaceuticals Inc Saturn-1 Pivotal Trial Topline Results Call TranscriptJun 21, 2021
Tarsus Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Great. Welcome, everyone, to the next session here at Raymond James 2021 Human Health Innovation Conference. My name is Dane. I'm one of the senior biotech analysts with Raymond James.
For this session, we're going to have a fireside chat with the CEO of Tarsus. Very happy to have you here, Bobby. It's going to be a great discussion, very well-timed for some really clinical -- important clinical data that you had this week.
But maybe for some of our audience members that are less familiar with the Tarsus story, you could just give us a brief intro on yourself and a little bit background in terms of Tarsus and then we can go into maybe some specific questions.
That's great, Dane. Thank you for having us here at the Raymond James conference. It is a really dynamic and exciting time at Tarsus. We just have read out our first pivotal trial, the first-ever pivotal trial for Demodex blepharitis, so we will tell you all
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)